NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Ovid Therapeutics Inc. OVID
11 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 7.3M
Revenue, FY2025 · full 11-year series below
Revenue $M
Net income $M
FY2025 · Revenue 7.3 · Net income -17.4
Compound annual growth
Revenue compounded at −10.5% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−240 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -585.2% · Net -240.1%
ROE
FY2025 · ROE -17.5%
Each USD of equity lost 18 cents this year.
The 11-year record
11 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | · | · | · | · | · |
| Operating income $B | −0.0 | −0.1 | −0.1 | −0.1 | 0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.1 | −0.1 | −0.1 | 0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · |
| Net income $B | −0.0 | −0.0 | −0.1 | −0.1 | 0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.1 | −0.0 | −0.1 | 0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | · | · | −0.74 | −0.77 | 1.76 | −1.39 | · | −2.11 | −3.35 | −2.28 | −1.36 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −17.5 | −33.9 | −47.6 | −34.7 | 110.0 | −142.6 | −111.1 | −85.0 | −97.7 | −38.2 | −19.3 |
| Shares out B | 0.13 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.05 | 0.02 | 0.02 | 0.01 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 39 reconciliationsAUDITED
Reconciled in 11 of 19 fiscal years. 37 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2015